Peer-reviewed veterinary case report
Auranofin with standard care helps dogs with bone cancer live longer
By Endo-Munoz, Liliana et al.·Published in Veterinary and comparative oncology·2020·Translational Research Institute, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Auranofin improves overall survival when combined with standard of care in a pilot study involving dogs with osteosarcoma.
- Species:
- dog
Plain-English summary
A group of dogs with osteosarcoma (a type of bone cancer) was treated with auranofin, a medication that may help reduce cancer spread, alongside standard treatments like amputation and chemotherapy. In this study, 40 dogs received auranofin, and the results showed that it improved overall survival, especially in male dogs. About 25% of the dogs in the treatment group were still alive without any signs of cancer after more than two years. This suggests that auranofin could be a promising addition to the treatment plan for dogs with osteosarcoma.
People also search for: dog osteosarcoma treatment · auranofin for dogs · dog cancer survival rates · osteosarcoma in male dogs · amputation and chemotherapy for dogs
Abstract
Osteosarcoma is the most common paediatric primary bone malignancy. The major cause of death in osteosarcoma is drug-resistant pulmonary metastasis. Previous studies have shown that thioredoxin reductase 2 is a driver of metastasis in osteosarcoma and can be inhibited by auranofin (AF). Moreover, studies have shown that AF significantly reduces pulmonary metastases in xenotransplant models. Here, we describe a phase I/II study of AF in canine osteosarcoma, a well-recognized spontaneous model of human osteosarcoma. We performed a single-arm multicentre pilot study of AF in combination with standard of care (SOC) (amputation + carboplatin). We recruited 40 dogs to the trial and used a historical SOC-only control group (n = 26). Dogs >15 kg received 9 mg AF q3d PO and dogs <15 kg received 6 mg q3d. Follow-up occurred over at least a 3-year period. Auranofin plus SOC improved overall survival (OS) (P = .036) in all dogs treated. The improved outcome was attributable entirely to improved OS in male dogs (P = .009). At the time of writing, 10 dogs (25%) survive without measurable disease in the treatment group with survival times ranging between 806 and 1525 days. Our study shows that AF improves OS in male dogs when combined with SOC. Our findings have translational relevance for the management of canine and human osteosarcoma. Our data justify a larger multicentre phase 2 trial in dogs and a phase I/II trial in human patients with refractory disease at the time of initial surgery.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31441983/